Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
Amanda Psyrri(National and Kapodistrian University of Athens), Tanguy Y. Seiwert(Georgetown University), Stefan Kasper(Essen University Hospital), Shunji Takahashi(Japanese Foundation For Cancer Research), Alejandro Yovine(AstraZeneca (United Kingdom)), Jared Weiss(University of North Carolina at Chapel Hill), Jérôme Fayette(Université Claude Bernard Lyon 1), J-P. Machiels(Cliniques Universitaires Saint-Luc), А. А. Карпенко(Leningrad Regional Cancer Center), Ihor Vynnychenko(Sumy State University), John F. Kurland(AstraZeneca (Netherlands)), Nassim Morsli(Boehringer Ingelheim (France)), Mikhail Dvorkin(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), S.C. Thungappa(Healthcare Global Enterprises), Brent Evans(AstraZeneca (United States)), V. Baker(AstraZeneca (United Kingdom)), Alexander Vasilyev(Russian Railways), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Richard F. Olsson(AstraZeneca (Netherlands)), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), Philip He(AstraZeneca (Japan)), Pedro Pérez Segura(Hospital Clínico San Carlos), Ching-Yun Hsieh(China Medical University), P. S. Mauz(University of Tübingen), Shrujal S. Baxi(Cambridge Health Alliance), M-J. Ahn(Samsung Medical Center), Sophie Wildsmith(AstraZeneca (United Kingdom))
Cited by 144
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k